Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05526573
Other study ID # 4393
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 14, 2022
Est. completion date December 31, 2025

Study information

Verified date January 2024
Source Azienda Sanitaria-Universitaria Integrata di Udine
Contact Alberto Fantin
Phone 0432-552550
Email alberto.fantin@asufc.sanita.fvg.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The use of an ultrathin bronchoscope (UB) has recently been introduced in the diagnosis of peripheral lung lesions. The use of the UB can be supported by navigation systems such as fluoroscopy, ultrasound guidance, electromagnetic navigation, or other technologies, which have complementary potential. Further navigation techniques are still under study. The use of ultrathin instrumentation has already been shown to significantly reduce procedural times compared to traditional instrumentation. The purpose of the study is to prospectively evaluate the institutional experience of different third-level hospital centers with the use of a UB (MP190F; Olympus Medical Systems, Tokyo, Japan) for sampling peripheral lung lesions by means of transbronchial needle aspiration (TBNA) or transbronchial biopsy (TBB), performed after fluoroscopic navigation and simultaneous radial probe-endobronchial ultrasound (RP-EBUS) assessment. Design: multicentric, observational study.


Recruitment information / eligibility

Status Recruiting
Enrollment 148
Est. completion date December 31, 2025
Est. primary completion date July 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Candidate for a diagnostic procedure for a new peripheral lung lesion or re-biopsy; - Tissue sampling of the peripheral lesion performed only with UB; - The patient's ability to understand the individual characteristics and consequences of the clinical study; - Males and females of any ethnicity; - Subjects who have given their informed consent to use their clinical data for research purposes. Exclusion criteria: - Inability to give informed consent or understand its contents; - Unavailability of tomographic imaging; - Failure to use RP-EBUS or fluoroscopic guidance during the procedure; - Failure to use R.O.S.E. by the pulmonologist or pathologist during the procedure; - Tissue sampling on the same peripheral lesion using an instrument of a different caliber in replacement or in association; - Any other significant illness or disorder that, in the investigator's opinion, may put the patient at risk due to study participation.

Study Design


Intervention

Device:
Ultrathin bronchoscopy (MP190F; Olympus Medical Systems, Tokyo, Japan)
Fluoroscopy + RP-EBUS and consecutive lesion sampling by TBNA and/or TBB

Locations

Country Name City State
Italy Pneumologia, Azienda Ospedaliero-Universitaria Ospedali Riuniti Ancona
Italy Pneumologia, Arcispedale S. Maria Nuova Reggio Emilia
Italy Pneumologia, ASUFC, Az. Osp. Santa Maria della Misericordia Udine

Sponsors (1)

Lead Sponsor Collaborator
Azienda Sanitaria-Universitaria Integrata di Udine

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the overall diagnostic accuracy Sensitivity, specificity, positive predictive value, negative predictive value Within 12 months from the procedure
Secondary Agreement between the definitive pathological result and the rapid on-site evaluation (R.O.S.E.) Comparison (% of concordant and % of discordant results) between R.O.S.E. (performed during the procedure by the pulmonologist or by the pathologist) and the final result obtained after the evaluation (by the pathologist) of the samples taken. Within 15 days from the procedure
Secondary Evaluation of patient satisfaction at the end of the procedure (Likert scale in relation to the memory of the procedure and the willingness to repeat it in the future.) Patients will undergo two satisfaction questionnaires, set according to Likert scale, at the end of the endoscopic procedure. Same day of the procedure
Secondary Correlation between the type of anesthesia, the characteristics of the lesion, the procedural dynamics and diagnostic accuracy Within 12 months from the procedure
Secondary Correlation between the type of anesthesia, the characteristics of the lesion, the procedural dynamics and patient satisfaction Correlations will be made between the anesthetic, radiological and procedural parameters with respect to the answers obtained in the satisfaction questionnaires. Same day of the procedure
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk